NewLink Genetics Appoints Eugene P. Kennedy, M.D., As Vice President For Clinical And Medical Affairs

AMES, IA--(Marketwired - Feb 26, 2014) - NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, today announced the appointment of Eugene P. Kennedy, M.D., FACS, as Vice President for Clinical and Medical Affairs. Dr. Kennedy will be responsible for clinical operations related to NewLink's HyperAcute® and IDO (indoleamine-(2,3)-dioxygenase) pathway product candidates as well as supporting commercial development strategies.

Help employers find you! Check out all the jobs and post your resume.